Abstract
Numerous studies have demonstrated that disturbances of the balance between coagulation and fibrinolysis affect the incidence of atherosclerosis-related clinical events. The most important markers of fibrinolytic activity are the levels of PAI-1 and tPA. Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of the plasminogen activators tPA and urokinase in the regulation of fibrinolytic balance. Disorders associated with increased thrombosis, such as coronary heart disease, are associated with increased PAI-1 antigen and activity and, in the case of coronary heart disease, decreased tPA activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
